top of page

1. Eye Examination

Our AI-based solution analyses data-rich images captured with existing retinal imaging cameras available in most eye clinics — this means that the experience is familiar and comfortable.

2. Data-Rich Images

Data-rich images of the retina are captured using high resolution retinal imaging providing the basis for detailed analysis and more accurate results. Each pixel has over 100 colors instead of just 3 (i.e., red, green, blue) in a regular color image. 

3. Explainable AI (XAI)

Automated Alzheimer’s detection uses artificial intelligence to help clinicians detect Alzheimer’s years before the emergence of clinical symptoms, with future possibilities of AI algorithms to aid healthcare professionals in identifying other diseases.

A Game-Changing Collaboration in Alzheimer's Detection

RetiSpec's solution draws on technology developed by Robert Vince, Ph.D., and Swati More, Ph.D., at the University of Minnesota's Center for Drug Design.

​

Among many incredible discoveries, Prof. Vince, invented one of the first blockbuster drugs for HIV, abacavir (Ziagen). Fortunately, Professor Vince continued his discoveries alongside Professor More when they developed the underlying method of using retinal hyperspectral imaging to detect Alzheimer's disease pathology with a simple eye exam. 

Publications

December 2023

Hyperspectral analysis of amyloid beta (Aβ) evolutional changes in preclinical to late-stage Alzheimer’s disease using matched brain and retinal tissue

M. Flanagan, B. Danner, C. Zamudio, C. Spencer, J. N. Lilek, A. Matos, M. Morris, K. Ajroud, W. Xie, C. Bornbaum, J. Westreich, S. More

October 2023

Implementing cognitive assessment and RetiSpec retinal screening in community-based settings: enhancing early detection of Alzheimer’s disease

S. Cohen, A. Kurzman, J. Giordano, R. Naureen, A. Hansen, M. Martinez, M. Bietenhader, N. Sohbati, N. Abdulla, C. Cameron, S. Estreicher, S. Semwel, C. Bornbaum

October 2023

RetiSpec’s AI-based retinal test: Results of a multi-site, prospective, validation study to predict brain Aβ pathology in a diverse population of adults with preclinical, mci, and probable Alzheimer’s disease.

A. Hazan, C. Bornbaum, E. Shaked, J. Giordano, Y. Edlitz, D. He, D. Kerwin

May 2023

RetiSpec: A promising approach to dementia screening through optometry.

Cohen S, Giordano J, Bornbaum C.

November 2019

In Vivo Assessment of Retinal Biomarkers by Hyperspectral Imaging: Early Detection of Alzheimer's Disease

S. More, J.M. Beach, C. McClelland, A. Mokhtarzadeh, R. Vince

June 2016

Early Detection of Amyloidopathy in Alzheimer's Mice by Hyperspectral Endoscopy

S. More; J.M. Beach, R. Vince

October 2014

Hyperspectral Imaging Signatures Detect Amyloidopathy in Alzheimer’s Mouse Retina Well before Onset of Cognitive Decline; ACS Chem.

S. More, R. Vince

Recent Conference Presentations

How can we facilitate adoption and scale for early detection of Alzheimer’s disease? Insights from implementing a community-based screening program using cognitive assessments and RetiSpec screening in Ontario, Canada Copy
Cohen S, Giordano J, Kurzman A, Hansen A, Martinez M, Sohbati N, Abdulla N, Cameron C, Estreicher S, Semwel S, Shaked E, Bornbaum C
Enhancing clinical trial efficiency: Increasing screening and randomization rates using RetiSpec’s AI-based eye scan for pre-screening in eye care settings
Lehr J, Grapentine S, Lenox B, Cassidy S, Naureen R, Pendarvis B, Giordano J, Hazan A, Shaked E, Bornbaum C.
Retinal hyperspectral imaging and blood-based biomarkers demonstrate comparable performance for predicting brain Aβ pathology: A head-to-head comparison from the Bio-Hermes-001 study
Grapentine S, Hazan A, Shaked E, Giordano J, Bornbaum C, Beauregard D.
Screening for Memory Concerns in Optometry Settings to Facilitate Early Detection of Alzheimer’s Disease:Measuring the Utility of the RetiSpec Scan
N. Sohbati, N. Abdulla, M. Bietenhader, J. Giordano, C. Bornbaum, S. Cohen
RetiSpec’s AI-based retinal test: Results of a multi-site, prospective, validation study to predict brain AB pathology in a diverse population of adults with Preclinical, MCI, and Probable Alzheimer’s disease
A. Hazan, C. Bornbaum, E. Shaked, J. Giordano, Y. Edlitz, D. He, D. Kerwin
Hyperspectral analysis of amyloid beta (Aβ) evolutional changes in preclinical to late-stage Alzheimer’s disease using matched brain and retinal tissue
M. Flanagan, B. Danner, C. Zamudio, C. Spencer, J.N. Lilek, A. Matos, M. Morris, K. Ajroud, W. Xie, C. Bornbaum, J. Westreich, S. More
Screening for memory concerns in community-based settings to facilitate early detection of Alzheimer's disease: Can optometry clinics serve as a useful venue?
S. Cohen, J. Giordano, A. Hansen, M. Martinez, N. Sohbati, M. Bietenhader, C. Bornbaum
Implementing cognitive assessment and RetiSpec retinal screening in community based settings: Enhancing early detection of Alzheimer's disease
S. Cohen, A. Kurzman, J. Giordano, R. Naureen, A. Hansen, M. Martinez, M. Bietenhader, N. Sohbati, N. Abdulla, C. Cameron, S. Estreicher, S. Semwel, C. Bornbaum
Clinical and Postmortem Analysis of Retinal Tissue
B. Danner, C.. Zamudio, C Spencer, J. Lilek, A. Matos, M. Morris, K. Ajroud, M.E. Flanagan
RetiSpec's Hyperspectral Imaging System: Results of a Validation Study in Preclinical AD and MCI
S. Cohen, A. Plante, A. Hazan, A. Gribble, Y.P. Lin, J. DiGregorio, J. Westreich, I. Cohen, A. Strilchuk, J. Soehner, F. Leblond, M. Schnaider-Beeri
Post-Mortem Retinal Analyses of Amyloid-Beta Oligomers in Alzheimer’s Disease
Danner, B., Zamudio, C., Spencer, C., Lilek, J., Matos, A., Morris, A., Ajroud, K., Flanagan, M.
bottom of page